[Transurethral endoscopic electrovaporization in the treatment of patients with benign prostatic hyperplasia]

A clinical trial of a novel low-invasive method--transurethral endoscopic electrovaporization (TUEV)--was initiated in the Research Institute of Urology in 1995. TUEV was tried in the treatment of benign prostatic hyperplasia (BPH). It is a variant of transurethral monopolar electrosurgery involving evaporation of the prostatic tissue by means of high-frequency powerful currents (200-300 W, 250-400 kHz) with simultaneous coagulation of the underlying layers in the absence of noticeable blood loss. TUEV of BPH was conducted in 60 patients aged from 56 to 80 years. The size of the prostate was within 40 cm3. The operation took 40 min maximum. Perioperative complications were absent. Subjective symptoms (IPSS scale), rectal, urodynamic and ultrasound findings documented 2-3 weeks and 3-6-12 months after TUEV evidence for considerable improvement of subjective symptoms, faster urine discharge, absence of residual urine. The conclusion is that TUEV is an effective low-traumatic surgical intervention in BPH of small or moderate size which can be used as BPH monotherapy.